<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234324</url>
  </required_header>
  <id_info>
    <org_study_id>AIO/CAO-STO-0801</org_study_id>
    <secondary_id>2008-007798-18</secondary_id>
    <nct_id>NCT01234324</nct_id>
  </id_info>
  <brief_title>ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction</brief_title>
  <acronym>NEOPECX</acronym>
  <official_title>An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely
      decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced
      adenocarcinoma of the stomach and gastroesophageal junction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of pT3/T4 categories after surgery</measure>
    <time_frame>after 9 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequencies of pN2/N3 categories after surgery</measure>
    <time_frame>After 9 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Gastroesophageal Junction Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1: ECX + Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: EXC alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Cisplatin, Capecitabine, Panitumumab</intervention_name>
    <description>Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.</description>
    <arm_group_label>Arm 1: ECX + Panitumumab</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Cisplatin, Capecitabine</intervention_name>
    <description>Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.</description>
    <arm_group_label>Arm 2: EXC alone</arm_group_label>
    <other_name>Vectibix®, Xeloda®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent to comprehend, sign, and date an IEC-approved informed consent form, written
             informed consent.

          -  Of either gender and aged 18 years or more.

          -  Diagnosed with histologically confirmed adenocarcinoma of the stomach or the
             gastroesophageal junction of Type I/II/III according to the classification of Siewert
             et al, 1996.

          -  Stage uT/3 or 4 N0/+ and M0 disease evaluated by endoscopic ultrasound, spiral
             computed tomography of the chest, abdomen and pelvis and by laparoscopy in uT3/T4
             tumors.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Leucocyte count &gt; 3,000/mm3.

          -  Platelet count ≥100,000/mm3.

          -  Haemoglobin ≥10 g/dl.

          -  Serum creatinine ≤ 1.5x of upper limit of normal (ULN).

          -  Creatinine clearance &gt; 60 ml/kg/min measured either by 24-h urine sampling or
             calculated by using the Cockcroft-Gault formula .

          -  Aspartate aminotransferase (AST) ≤3 x ULN.

          -  Alanine aminotransferase (ALT) ≤3 x ULN.

          -  Bilirubin ≤ 1.5 x ULN.

          -  Magnesium ≥ lower limit of normal.

          -  Calcium ≥ lower limit of normal.

          -  Subject is deemed a good candidate for surgery.

        Exclusion Criteria:

          -  Any metastatic disease.

          -  Other malignant tumours less than five years old. Exceptions include basocellular
             carcinoma, in situ cancer of the cervix of the uterus, or any curatively-treated other
             malignancies without evidence of disease for more than five years.

          -  Significant ascites or pleural effusion.

          -  Prior anti-EGFr antibody therapy (e.g. cetuximab) or treatment with small molecule
             EGFr tyrosine kinase inhibitors (e.g. erlotinib).

          -  Prior chemotherapy, radiotherapy or antibody therapy for gastric cancer or cancer of
             the gastro-oesophageal junction.

          -  Concomitant therapy with sorivudine or analogue compounds.

          -  Known previous or ongoing abuse of narcotic drug, other medication or alcohol.

          -  Significant cardiovascular disease including New York Heart Association (NYHA) grade
             II or greater congestive heart failure, peripheral arterial occlusive disease stage II
             or greater, symptomatic coronary heart disease, insufficiently treated arterial
             hypertension, unstable angina or myocardial infarction within 12 months before
             initiating study treatment or a history of ventricular arrhythmia.

          -  History or evidence upon physical examination of CNS disease unless adequately
             treated, seizure not controlled with standard medical therapy, or history of stroke.

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest CT scan.

          -  Pre-existing polyneuropathy grade &gt;1 according to the National Cancer Institute's
             Common Terminology Criteria for Adverse Events (NCI CTCAE), except for loss of tendon
             reflex as the only symptom.

          -  Treatment for systemic infection within 14 days before initiating study treatment.

          -  Active inflammatory bowel disease, serious gastric ulceration or other bowel disease
             causing chronic diarrhoea (defined as &gt; 4 loose stools per day).

          -  Suspected or known dihydropyrimidine dehydrogenase deficiency (DPD).

          -  Thrombosis or severe bleeding within six months prior to entry into the study (except
             for bleeding of the tumour before its surgical resection), evidence of bleeding
             diathesis or coagulopathy, or current or recent (within 10 days prior to initiation of
             study treatment) use of full-dose oral or parenteral anticoagulants for therapeutic
             purposes.

          -  History of any medical condition that may increase the risks associated with study
             participation or may interfere with the interpretation of the study results.

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus or
             chronic active hepatitis B infection.

          -  Known allergy to the investigational product, to any of its excipients, to monoclonal
             antibodies, or to any of the components of the chemotherapy regimen.

          -  Any co-morbid disease that would increase risk of toxicity.

          -  Any kind of disorder that compromises the ability of the subject to give written
             informed consent and/or comply with the study procedures.

          -  Any investigational agent or participation in another clinical trial within 30 days
             prior to randomisation.

          -  Must not have had a major surgical procedure within 28 days of randomisation.

          -  Subject who is pregnant or breast feeding.

          -  Woman or man of childbearing potential not consenting to use adequate contraceptive
             precautions (intrauterine contraceptive device, contraceptive implants, injectables
             (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual
             abstinence or vasectomised partner) during the course of the study and for six months
             after the last study drug administration for women and men. Post-menopausal women must
             have been amenorrheic for at least 12 months to be considered of non-child-bearing
             potential.

          -  Subject unwilling or unable to comply with study requirements.

          -  Hearing impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Stahl, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinken Essen-Mitte Evang. Huyssens-Stiftung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIO-Studien gGmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Arbeitsgemeinschaft der internistischen Onkologie</description>
  </link>
  <reference>
    <citation>Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003 Oct 1;98(7):1521-30.</citation>
    <PMID>14508841</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.</citation>
    <PMID>16822992</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):337-45.</citation>
    <PMID>15269313</PMID>
  </reference>
  <reference>
    <citation>García I, del Casar JM, Corte MD, Allende MT, García-Muñiz JL, Vizoso F. Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer. Int J Biol Markers. 2003 Jul-Sep;18(3):200-6.</citation>
    <PMID>14535591</PMID>
  </reference>
  <reference>
    <citation>Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33.</citation>
    <PMID>10735013</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Gastroesophageal Junction Neoplasms</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>cancer of the gastroesophageal junction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

